Erudio Healtherudio.com
Drug
Goserelin trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying goserelin: VA STARPORT. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 11 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| VA STARPORT NCT04787744 · VA Office of Research and Development | oligometastatic prostate cancer | Phase 2/Phase 3 | 119 | 25 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RIGHT Choice NCT03839823 · Novartis Pharmaceuticals DeepView → | premenopausal or perimenopausal HR-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| MONALEESA-7 NCT02278120 · Novartis Pharmaceuticals DeepView → | premenopausal HR-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| BYLieve NCT03056755 · Novartis Pharmaceuticals DeepView → | PIK3CA-mutated HR+ HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| ROSALINE NCT04551495 · Jules Bordet Institute DeepView → | ER+ HER2-negative invasive lobular breast carcinoma | Phase 2 | Deep | View | |||
| PREDICT-RT NCT04513717 · NRG Oncology DeepView → | high risk prostate cancer | Phase 3 | Deep | View | |||
| PR-7 NCT00003653 · NCIC Clinical Trials Group StandardView → | prostate cancer with rising PSA after radiotherapy | Phase 3 | Standard | View | |||
| RADICALS NCT00541047 · University College, London FocusedView → | prostate cancer after radical prostatectomy | Phase 3 | Focused | View | |||
| PCS IX NCT02685397 · Sir Mortimer B. Davis - Jewish General Hospital FocusedView → | castration-resistant prostate cancer with oligometastases | Phase 2/Phase 3 | Focused | View | |||
| NCT03678025 NCT03678025 · SWOG Cancer Research Network FocusedView → | Not given | Phase 3 | Focused | View | |||
| AMALEE NCT03822468 · Novartis Pharmaceuticals FocusedView → | first-line HR-positive HER2-negative advanced breast cancer | Phase 2 | Focused | View | |||
| INDICATE NCT04423211 · ECOG-ACRIN Cancer Research Group FocusedView → | Not given | Phase 3 | Focused | View | |||